FDA Approves Actemra For the Treatment of Rheumatoid Arthritis
FLINT, Mich.— Nov. 07, 2013 —On Monday, October 21, 2013, the U.S. Food and Drug Administration approved a subcutaneous formulation of Actemra® (tocilizumab). This new product was approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Methotrexate is an example of a DMARD. Tocilizumab may be used alone or as a component of a combination therapy regimen consisting of methotrexate or other non-biologic DMARDs. The subcutaneous product will be available as 162 mg single-use prefilled syringes. The product is expected to be available in November 2013.
Actemra® was previously approved as an intravenous (IV) infusion for the treatment of RA, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA). Diplomat will be able to distribute this medication when it is available.
For more information about our support services for patients with rheumatoid arthritis, visit our website. You may also contact us directly at 877.977.9118 or, if your inquiry is not urgent, email us at email@example.com.
@DiplomatRx@JNJNews treatment Zytiga significantly cut the death risk for ... prostate cancer patients by 38% https://t.co/6Ga1okf4Ye @ASCO #ASCO174 days ago
@sloan_ketteringRT @sloan_kettering: Your immune system provides one of the best defenses against cancer. But sometimes it needs a little help. More about…2 weeks ago
@DiplomatRxThank you to @corpmagazine for recognizing Diplomat as a 2017 Michigan Economic Bright Spot awardee!2 weeks ago
@DiplomatRxFriend and Patient Advocate, Brenda Williams Hawkes was featured in @MyGoodDays Days this month!… https://t.co/TFGSoMecqO2 weeks ago
@DiplomatRxJeff Park Elected to Diplomat Board of Directors https://t.co/IMI1aRwNbm3 weeks ago